Guangdong Hybribio Biotech Co.,Ltd. Stock: price and insider trades · China
凯普生物
No insider purchase over the last 90 days. The latest, by 王建瑜, was filed 09 Jan 2026.
Guangdong Hybribio Biotech Co.,Ltd.: what insiders have been doing
Guangdong Hybribio Biotech Co.,Ltd. is a Health Care company. Its directors and officers file their transactions with SSE / SZSE (CSRC). In the past year (5 November 2025 to 5 November 2026), 2 filings came from 2 insiders.
Both sides are active: 1 purchase worth €2.2M and 1 sale worth €65k, from 1 insider and 1 insider respectively. On balance, insiders were net buyers of €2.2M. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Those buying include 1 board member. The largest single trade was a purchase of €2.2M by 王建瑜, published on 9 January 2026.
The most recent open-market purchase was published on 9 January 2026, 304 days ago.
Compared with its exchange (521 companies, median 2 filings), a count of 2 filings is typical. Looking back to 2023, when coverage begins, insiders filed 1 purchase and 2 sales.
In the same sector, recent insider purchases at Dynavox Group AB and Vetoquinol SA also feature in our signals. These figures are compiled from regulatory filings published by SSE / SZSE (CSRC). They describe what insiders did and are not a recommendation.
Who traded when
BuySaleSince the insiders bought
- -2.6%Entry CN¥5.74 · Close 03 Nov 2026 CN¥5.59
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
About Guangdong Hybribio Biotech Co.,Ltd.
凯普生物 is a company focused on the healthcare and pharmaceutical sector, specializing in the development of biopharmaceutical solutions. It is listed on the XSHE market.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
